Hepatitis B articles from across Nature Portfolio

Acute-on-chronic liver failure (ACLF) is characterized by rapid deterioration of liver function in patients with chronic liver disease. Here, the authors show that BTLA expression in CD4⁺ T cells is associated with disease severity and inflammation in hepatitis B virus-related ACLF.

Here, English et al. show that after expanding in lymphoid tissues, CD4⁺ and CD8⁺ T cells recognising hepatic antigens migrate into specialised vascular liver areas where CD4⁺ T cells locally license hepatic dendritic cells and further expand CD8⁺ T cell numbers.

Interim analysis of the SHIELD program, adopting multilevel interventions, showcases low mother-to-child transmission (MTCT) rates of hepatitis B virus (HBV) across different hospital and community settings in China.

Hepatitis B virus (HBV) core protein-targeting compounds are in or entering clinical development without a standardized nomenclature. We propose a naming convention for these core-targeting antiviral products to provide clarity and accelerate HBV drug development.

Advances in hepatitis B management are still not reaching most of the affected community. A major barrier to this translation is stigma. Research and clinical communities have a responsibility to mitigate stigma and ensure that the voices of the affected community are considered in decision-making conversations.

Vaccination is a key intervention for the elimination of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections to fulfil the WHO’s 2030 global elimination goal. Innovations in 2021 promise to curb HBV transmission by reducing mother-to-child transmission and enhancing vaccine immunogenicity in at-risk adult groups. Additionally, an HCV vaccination trial was conducted, and there were also advances in our understanding of the immunology underpinning the lack of protection against HCV reinfection.